|
Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer. |
|
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Inivata; Merck; Novartis; Pfizer; Regeneron; Symphogen |
Research Funding - Abbvie (Inst); Astellas Pharma; Bristol-Myers Squibb; EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Regeneron (Inst); Tizona Therapeutics, Inc.; Transgene |
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA. |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Merck; Regeneron |
|
|
Employment - University of California |
Leadership - International Journal of Radiation Oncology Biology Physics; Practical Radiation Oncology |
Consulting or Advisory Role - Boston Scientific; Triptych Health Partners |
Research Funding - EMD Serono; Genentech (Inst) |
Travel, Accommodations, Expenses - Boston Scientific |
Other Relationship - Telesecurity Sciences/Imatex |
|
|
|
Consulting or Advisory Role - HealthHelp |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Heron; Loxo; Medtronic; Spectrum Pharmaceuticals |
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst) |
|
|
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Celgene; Clinica Alemana; Dynamo Therapeutics; EMD Serono; Moderna Therapeutics; Pierre Fabre; Shattuck Labs; Torque |
Speakers' Bureau - Bristol-Myers Squibb; Fluidigm; Merck |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; Moderna Therapeutics; Navigate BioPharma; Pierre Fabre; Surface Oncology; Takeda; Tesaro |
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES) |
|
|
No Relationships to Disclose |